Xencor Inc. (XNCR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Xencor Inc. (XNCR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

19.15

-1.11 (-5.48%)

At close: Jan 14, 2025, 3:59 PM

19.11

-0.21%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	7.65
Market Cap	1.34B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.18
PE Ratio (ttm)	-6.02
Forward PE	n/a
Analyst	Buy

Ask	30.35
Volume	418,285
Avg. Volume (20D)	621,921
Open	20.50
Previous Close	20.26
Day's Range	19.05 - 20.50
52-Week Range	15.31 - 27.24
Beta	undefined

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with r...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 3, 2013

Employees 280

Stock Exchange NASDAQ

Ticker Symbol XNCR

Website https://www.xencor.com

Analyst Forecast

According to 9 analyst ratings, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 82.77% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Xencor Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $13.93M, reflecting a -68.83% YoY shrinking and earnings per share of -0.86, making a 177.42% increase YoY.

Why Price Moved

4 months ago · Source

+10.45%

Xencor shares are trading higher. The company pric... Unlock content with Pro Subscription

4 months ago · Source

+22.93%

Xencor shares are trading higher after the company announced four new XmAb programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs.

News

22 hours ago · zacks.com

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 month ago · zacks.com

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv...

1 month ago · businesswire.com

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

1 month ago · seekingalpha.com

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of...

1 month ago · zacks.com

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago · zacks.com

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple m...

2 months ago · zacks.com

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago.

2 months ago · businesswire.com

Xencor Reports Third Quarter 2024 Financial Results

2 months ago · businesswire.com

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, toda...

2 months ago · zacks.com

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago · zacks.com

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago · zacks.com

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv...